Newsfeeds - Spark Newswire

1 minute read

News

Looking Into Biodesix’s Return On Capital Employed

Today, 9:09 AM

During Q1, Biodesix's (NASDAQ:BDSX) reported sales totaled $28.87 million. Despite a 110.44% in earnings, the company posted a loss of $5.58 million. In Q4, Biodesix brought in $27.03 million in sales but lost $2.65 million in earnings.

BDSX

6 minute read

The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda

By Shanthi Rexaline

Today, 9:09 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14)

ACHL

2 minute read

Biodesix Announces Commercial Availability Of SARS CoV-2 Neutralization Antibody Test

By Bill Haddad

Today, 9:09 AM

Detection of circulating neutralizing antibodies produced in response to COVID-19 vaccination and infection may benefit immunocompromised individuals. Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic

BDSX

2 minute read

Biodesix Reports Partnership With Datavant To Enhance Value Of Lung Cancer Databank, No Terms Disclosed

By Benzinga Newsdesk

Today, 9:09 AM

Biodesix intends to make its databank and linked data accessible to research and biopharma partners BOULDER, Colo. & SAN FRANCISCO--(BUSINESS WIRE)-- Biodesix, Inc. (NASDAQ:BDSX), a leading lung cancer

BDSX

1 minute read

News

Biodesix: Return On Capital Employed Insights

By Benzinga Insights

Today, 9:09 AM

During Q1, Biodesix's (NASDAQ:BDSX) reported sales totaled $28.87 million. Despite a 110.44% in earnings, the company posted a loss of $5.58 million. Biodesix collected $27.03 million in revenue during Q4, but reported earnings showed a $2.65 million loss.

BDSX